Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

CA64134N2032
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG01GP1RJJ2
NURL
Neural Therapeutics Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Neural Therapeutics Inc.
ISIN
CA64134N2032
TICKER
NURL
MIC
XCNQ
REUTERS
NURL.CD
BLOOMBERG
NURL CN
Fr., 19.06.2026       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions provided under Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Ventu...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.06.2026       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce the results of its annual general and special meeting of shareholders held on May 25, 2026 (the "Meeting"), including shareholder approval of the acquisition by Neural of the remaining 69.25% equit...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 19.05.2026       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - May 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 01.05.2026       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - May 1, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, announces that it has filed on SEDAR+ and completed the mailing of its...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 27.03.2026       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - March 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has entered into a second amending agreement (the "SIO Amendment") to its strategic investment and option agreement dated May 26, 2025, as previously amended (the "SIO Agreement"), with CWE European Ho...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 19.02.2026       Neural Therapeutics
CA64134N2032

VANCOUVER, BC, Feb. 19, 2026 /CNW/ - Trading resumes in: Company: Neural Therapeutics Inc.CSE Symbol: NURLAll Issues: YesResumption (ET): 11:30 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the nati...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 19.02.2026       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - February 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has formally applied to the Canadian Securities Exchange (the "CSE") for approval to acquire the remaining 69.25% interest in CWE European Holdings Inc. ("CWE"), operating as Hanf.com,...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 19.02.2026       Neural Therapeutics
CA64134N2032

VANCOUVER, BC, Feb. 19, 2026 /CNW/ - The following issues have been halted by CIRO: Company: Neural Therapeutics Inc.CSE Symbol: NURL All Issues: YesReason: Pending News Halt Time (ET): 8:14 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ens...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 19.02.2026       Neural Therapeutics
CA64134N2032

Instrument ID [23290954] (HANF - CA64134N2032) suspended...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 10.02.2026       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 27.01.2026       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - January 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("C...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 06.11.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - November 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("C...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 08.10.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - October 8, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on therapeutic solutions for mental health conditions, together with its portfolio company CWE European Holdings Inc. ("CWE", operating as Hanf.com), one of Germany's l...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 23.09.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - September 23, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for substance use disorders, together with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CB...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 13.08.2025       Neural Therapeutics
CA64134N2032

Transaction transforms Neural into company with solid financial fundamentals with significant short, mid and long-term growth prospects Hanf.com achieved sales of €4.9 Million (~CA$7.5M) and a 13% operating profit in 20241. Toronto, Ontario--(Newsfile Corp. - August 13, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or th...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 22.07.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - July 22, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 21.07.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - July 21, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce two major developments that strengthen its ethnobotanical...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 06.06.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of the Germany'...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 28.05.2025       Neural Therapeutics
CA64134N2032

VANCOUVER, BC, May 28, 2025 /CNW/ - Trading resumes in: Company: Neural Therapeutics Inc. CSE Symbol: NURL All Issues: Yes Resumption (ET): 2:30 PM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 28.05.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as Hanf.com, a leading Germ...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 28.05.2025       Neural Therapeutics
CA64134N2032

VANCOUVER, BC, May 28, 2025 /CNW/ - The following issues have been halted by CIRO: Company: Neural Therapeutics Inc. CSE Symbol: NURL All Issues: Yes Reason: Pending News Halt Time (ET): 9:24 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 13.05.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - May 13, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, announces that the Board of Directors approved the grant of 2,720,000 restricted s...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 09.05.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - May 9, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that it has submitted a renewal application to Servic...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 16.04.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - April 16, 2025) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for March 2025.March 2025 Operating StatisticsTrading volume of CSE listed securities totaled 1.1 billion shares;Trading value of CSE listed securities was $296 million;CSE issuers completed 85 financing...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 14.04.2025       Neural Therapeutics
CA64134N2032

Treatment of Major DSM-5 Disorders, Including Addiction, Depression and Anxiety, With Sub-Hallucinogenic Mescaline DosesExtraction Technology Delivering Higher Yields and Greater PurityFrankfurt Stock Exchange Ticker Symbol Changed to "HANF"Extension of LOI with CWE European Holdings (dba Hanf.com) Toronto, Ontario--(Newsfile Corp. - April 14, 2025...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 31.03.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - March 31, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: M6B) ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that shares of the company have commenced trading on the...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 17.03.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - March 17, 2025) - he Canadian Securities Exchange ("CSE" or "the Exchange") today welcomed the listing of Neural Therapeutics Inc. ("Neural Therapeutics" or the "Company"). The Toronto-based company has completed a private placement financing, and its common shares have been approved for listing on the CSE under...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 17.03.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - March 17, 2025) - Neural Therapeutics Inc. (CSE: NURL) ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that its common shares will commence trading on the Canadian Securi...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 14.03.2025       Neural Therapeutics
CA64134N2032

Toronto, Ontario--(Newsfile Corp. - Le 13 mars/March 2025) - The common shares of Neural Therapeutics Inc. have been approved for listing on the CSE. Listing and disclosure documents will be available at www.thecse.com on the trading date. Neural Therapeutics is an ethnobotanical drug discovery company, focusing on the d...
Zur Nachricht
Neural Therapeutics
Charts & Research Termsheets Terminal
Permalink